Drug Trial Radar · NCT02954991
Phase 2 Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Non-Small Cell Lung Cancer
Last checked: Nov 19, 2026Latest source record: Apr 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
161
Actual
Start
Nov 7, 2016
Primary completion
Nov 4, 2021
Study completion Nov 4, 2021
Sponsor
- Lead sponsor
- Mirati Therapeutics Inc.Bristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Nov 4, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study will evaluate the clinical activity of nivolumab in combination with 3 separate investigational agents, glesatinib, sitravatinib, or mocetinostat.
Conditions
- Carcinoma, Non-Small-Cell Lung
Interventions
GlesatinibDrug
Glesatinib is a small molecule multi-targeted receptor tyrosine kinase inhibitor
SitravatinibDrug
Sitravatinib is a small molecule inhibitor of receptor tyrosine kinases.
MocetinostatDrug
Mocetinostat is an HDAC inhibitor.
NivolumabDrug
nivolumab is a programmed death receptor-1 (PD-1) blocking antibody
Primary outcomes
What the sponsor says the trial is designed to measure.
- Objective Response Rate (ORR) as Defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1.Time frame: Up to 40.6 months
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Yuma Regional Medical Center
Yuma, Arizona
Beverly Hills Cancer Center
Beverly Hills, California
City of Hope National Medical Center
Duarte, California
University of California San Diego
La Jolla, California
University of California San Francisco Comprehensive Cancer Center
San Francisco, California
University of California Los Angeles - Torrance - Community Cancer Care
Santa Clarita, California
Rocky Mountain Cancer Centers - Denver - Midtown
Denver, Colorado
Baptist Health
Louisville, Kentucky
Henry Ford Hospital
Detroit, Michigan
Minnesota Oncology Hematology, P.A.
Minneapolis, Minnesota
University of Minnesota Masonic Cancer Center
Minneapolis, Minnesota
Saint Francis Cancer Treatment Center
Grand Island, Nebraska
Oncology Hematology Care-Blue Ash
Cincinnati, Ohio
University Hospitals Cleveland Medical Center
Cleveland, Ohio
Ohio State University Comprehensive Cancer Center
Columbus, Ohio
Hematology Oncology Associates - Barnett Office
Medford, Oregon
Northwest Cancer Specialists, P.C.
Tualatin, Oregon
Fox Chase Cancer Center
Philadelphia, Pennsylvania
Vanderbilt University
Nashville, Tennessee
Texas Oncology - South Austin
Austin, Texas
USOR - Texas Oncology - Denison Cancer Center
Denison, Texas
MD Anderson Cancer Center
Houston, Texas
Texas Oncology - Tyler
Tyler, Texas
Virginia Cancer Specialist
Fairfax, Virginia
University of Wisconsin
Madison, Wisconsin
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.